31
Views
11
CrossRef citations to date
0
Altmetric
Research Article

SUPPRESSIVE EFFECT OF PULMONARY HYPERTENSION AND LEUKOCYTE ACTIVATION BY INHALED PROSTAGLANDIN E 1 IN RATS WITH MONOCROTALINE-INDUCED PULMONARY HYPERTENSION

, , , , &
Pages 265-273 | Published online: 02 Jul 2009
 

Abstract

The effect of long-term prostaglandin E 1 (PGE 1) aerosol was investigated in rats with chronic pulmonary hypertension induced by monocrotaline (MCT). Six-week-old Sprague-Dawley rats were separated into groups of 6 and administered 1 mL of saline (group A) or 60 mg / kg of MCT. The MCT-treated mice were then administered either nothing (group B) or 5 mL of PGE 1 (4 μ g/mL) via a nebulizer every day for 1 week (group C), 2 weeks (group D), 3 weeks (group E), or 4 weeks (group F) after MCT injection. The pulmonary artery medial wall thickness was measured and the weight ratio of the right ventricle to the intraventricular septum plus the left ventricle (RV ratio) was determined 1 month after saline or MCT injection. Leukocytes positive for the activation markers CD18, CD49d, CD62L were determined in each group every week for 1 month. The pulmonary artery medial wall thickness and RV ratio gradually decreased in proportion to the duration of PGE 1 inhalation. In groups E and F, the level of CD62L-positive leukocytes gradually decreased after MCT injection in proportion to the duration of PGE 1 inhalation. We conclude that long-term inhalation of PGE 1 is very useful therapy in chronic pulmonary hypertension and that the antileukocyte effect of PGE 1 is associated with the suppression of CD62L-positive leukocytes at an early stage of progression.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.